Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Cash: 2009-2024

Historic Change in Cash for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$2.9 million.

  • Heron Therapeutics' Change in Cash rose 261.01% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 290.03%. This contributed to the annual value of -$2.9 million for FY2024, which is 121.60% down from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Cash of -$2.9 million as of FY2024, which was down 121.60% from $13.3 million recorded in FY2023.
  • Heron Therapeutics' Change in Cash's 5-year high stood at $33.2 million during FY2020, with a 5-year trough of -$75.2 million in FY2022.
  • Over the past 3 years, Heron Therapeutics' median Change in Cash value was -$2.9 million (recorded in 2024), while the average stood at -$21.6 million.
  • In the last 5 years, Heron Therapeutics' Change in Cash tumbled by 415.02% in 2022 and then skyrocketed by 117.71% in 2023.
  • Heron Therapeutics' Change in Cash (Yearly) stood at $33.2 million in 2020, then tumbled by 143.91% to -$14.6 million in 2021, then crashed by 415.02% to -$75.2 million in 2022, then skyrocketed by 117.71% to $13.3 million in 2023, then crashed by 121.60% to -$2.9 million in 2024.